

MIRNA THERAPY FOR GLIOBLASTOMA TREATMENT

INDRANIL MONDAL



DEPARTMENT OF BIOCHEMICAL ENGINEERING AND
BIOTECHNOLOGY

INDIAN INSTITUTE OF TECHNOLOGY DELHI

DECEMBER 2023

© Indian Institute of Technology Delhi (IITD), New Delhi, 2023

MIRNA THERAPY FOR GLIOBLASTOMA TREATMENT

by

INDRANIL MONDAL

DEPARTMENT OF BIOCHEMICAL ENGINEERING AND BIOTECHNOLOGY

Submitted

In fulfillment of the requirements of the degree of Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

DECEMBER 2023

Dedicated to my loved ones

CERTIFICATE

This is to certify that the thesis entitled “miRNA therapy for Glioblastoma treatment”, being submitted by Mr. Indranil Mondal to the Indian Institute of Technology Delhi, for the award of degree of Doctor of Philosophy, is a record of bonafide research work carried out by him, which has been prepared under my supervision and guidance of conformity with the rules and regulations of Indian Institute of Technology Delhi. The research reports and the results presented in this thesis have not been submitted in part or full to any other University/ Institute for the award of any degree or diploma.

Prof. Ritu Kulshreshtha

Professor and Head

Department of Biochemical Engineering and Biotechnology

Indian Institute of Technology Delhi

New Delhi- 110016.

Date:

Place: New Delhi, India

ACKNOWLEDGEMENTS

The long and arduous journey of my Ph.D. would not have been possible without the guidance, help, and support of many. I most humbly acknowledge those who stood beside me throughout this difficult yet exciting journey.

At the outset, I would like to express my sincere gratitude to my supervisor, Prof. Ritu Kulshreshtha, who has been a fantastic mentor for the last six years. Her constant guidance, constructive criticism, and experimental troubleshooting skills have helped me design and execute complex experiments. She has always motivated me to do better science, pushed me when I became negligent, and appreciated me when I did well. I am also extremely grateful to her for supporting me with an academic honorarium when I struggled. Spending time in her lab has increased my knowledge of cancer biology, boosted my confidence, and motivated me to continue my academic journey.

I express my sincere thanks to my student research committee (SRC) members, Prof. Prashant Mishra, Prof. Preeti Srivastava, and Prof. Archana Chugh for regularly monitoring my research progress for the past six years and providing their valuable inputs and suggestions that improved my thesis significantly. I am also grateful to all other faculty members and staff of the Department of Biochemical Engineering and Biotechnology, IIT Delhi for their continuous support.

I thank my collaborators across various institutions for actively contributing to my research career. Firstly, I would like to thank Prof. Sunil Kumar Khare (Dept. of Chemistry, IIT Delhi) and his student Syeda for helping design the anti-miR nanocarrier and actively contributing to our manuscript. Prof. Sagar Sengupta (NII, Delhi) and his student Dr. Swati Priya, deserve my sincere gratitude for helping with the animal studies. Further, I would like to thank Prof. Durga Prasad Mishra (CDRI, Lucknow) and his student Neelam for their fruitful collaboration. I thank Dr. Chitra Sarkar and Dr. Vikas Sharma for providing patient RNA samples from AIIMS, Delhi. I also thank Prof. Ashis Kumar Patra for collaborating with us actively for the last few years.

In this substantially long period of time, I have hustled alongside many great minds in this lab. I want to convey my heartfelt thanks and gratitude towards everyone I have worked with. My loving seniors taught me all the necessary techniques of molecular and cancer biology. I humbly

thank Shivani, Sonam, Omkar, Srishti, and Anirban for their guidance and love over the years. I thank my good friends Anubha, Amit, and Mansi for all the happy memories that helped me manage the academic stress of my Ph.D. life. My Juniors Garima, Ravi, Nidhi, Rajat, Anuja, Rahul, Aastha, Anuj, Shravya, Ritanksha, Anadi, Deepsikha, Vanshika, Ishita, Mansi, and Manisha deserve a lot of thanks for their constant support throughout my journey. Special thanks to Rajat, Garima, Srishti, Anubha, Anuja, Dr. Hima and Anirban for their unconditional love and assistance. You were like family, away from home. I also thank Dr. Vikas Sharma and Dr. Shraddha Chakraborty for their inspiration. I sincerely thank all the lab attendants of our lab: Yogesh, Sanjay, Arun, Arjun, and Mukesh, for their help in maintaining the lab.

I would like to acknowledge the Ministry of Education, Government of India, for financial support during my research work.

My parents, Mr. Manoranjan Mandal and Mrs. Ashalata Mondal, who have struggled a lot to give me happiness and watch me succeed, deserve my humble regards and most sincere gratitude. Without your constant love and guidance, I could not reach here. My dear elder brother Somnath Mondal and his wife, Mrs. Runu Gayen Mondal, deserve special thanks for always supporting my endeavors and cheering for me. I would also like to thank my in-laws sincerely, Mr. Kallol Kumar Mukhopadhyay and Mrs. Mitra Mukhopadhyay, for their continuous love, motivation, and support. Lots of love to Aditi, Saksham, Kasturi, and Sayan for always being there.

Finally, I thank Dr. Koel Mukherjee, my best friend and wife, for her unconditional love, patience, and immense support throughout the ups and downs of my Ph.D. journey, which I shall never forget. It is her unwavering faith in me and constant motivation that helped me reach the finishing line of my doctoral journey. My dear daughter Kojagori was born near the end of my Ph.D., and her innocent giggles and unconditional love motivated me to be better for her. I hope she reaches great heights in her life. I dedicate this thesis to my wife, daughter, and loving family.

Indranil Mondal

Date

ABSTRACT

Glioblastoma (GBM), the most aggressive central nervous system (CNS) tumor, remains incurable despite medical progress. Understanding GBM's molecular processes is vital for therapy development. In recent years, microRNAs (miRNAs) have been found to exhibit altered expression in GBM and other cancers, influencing key hallmarks. This study focuses on miR-210, a highly oncogenic miRNA in GBM, and aims to unravel its role in reprogramming energy metabolism – an emerging hallmark of cancer. To uncover its role in tumor metabolism, aldehyde dehydrogenase 5 family member A1 (ALDH5A1) was identified and validated as a direct target of miR-210 in GBM. Here, we report the role of miR-210/ALDH5A1 axis in GBM metabolism for the first time. We show that ALDH5A1 is downregulated in GBM patients and play an important role in cellular metabolism. By measuring various parameters like glucose uptake, extracellular lactate, ATP, and extracellular acidification rate (ECAR), we demonstrate that miR-210 promotes the glycolysis of GBM while ALDH5A1 inhibits it. We also demonstrate that ALDH5A1 overexpression significantly increases the oxygen consumption rate (OCR) GBM cells, while miR-210 inhibits mitochondrial respiration. Finally, we established a tumor suppressor role of ALDH5A1 in GBM where it inhibited cellular proliferation, 3D-spheroid formation, and reactive oxygen species (ROS) accumulation. Additionally, the study explores miR-210 as a potential therapeutic target and introduces a novel nanocarrier designed for the *in vitro* delivery of anti-miR-210 to GBM cells. Considering the challenges of delivering small RNA-based therapeutics into cells, a unique transglutaminase (TGase)-based nanocarrier was developed, designed in the shape of a blooming flower. These TGase nanoflowers (TGNFs), functionalized with PEI and with a mean diameter of 61nm, effectively complexed with anti-miR-210, enhancing its cellular uptake and facilitating its downregulation. The TGNFs exhibited >90% encapsulation efficiency for anti-miR-210, demonstrated non-cytotoxicity, did not adversely affect the liver and kidney health of CD1 mice, protected the cargo from serum nucleases, and prevented replacement by other polyanion moieties. Delivering anti-miR-210 to GBM cell lines U-87 MG and LN229 using the TGNFs led to a substantial reduction in cellular proliferation and migration, along with the induction of apoptosis. Overall, this research validates a novel target of miR-210, sheds light on its role in GBM metabolism, and presents a unique nanocarrier for delivering its antagonist to GBM cells.

सार

ग्लियोब्लास्टोमा (जीबीएम), सबसे आक्रामक सीएनएस ट्यूमर, चिकित्सा प्रगति के बावजूद लाइलाज बना हुआ है। जीबीएम की आणविक प्रक्रियाओं को समझना चिकित्सा विकास के लिए महत्वपूर्ण है। हाल के वर्षों में, माइक्रोआरएनए (एमआईआरएनए) को जीबीएम और अन्य कैंसर में परिवर्तित अभिव्यक्ति प्रदर्शित करते हुए पाया गया है, जो प्रमुख लक्षणों को प्रभावित करते हैं। यह अध्ययन एमआईआर-210 पर केंद्रित है, जो जीबीएम में एक अत्यधिक ऑन्कोजेनिक एमआईआरएनए है, और इसका उद्देश्य ऊर्जा चयापचय को पुनः प्रोग्राम करने में इसकी भूमिका को उजागर करना है - जो कैंसर की एक उभरती हुई पहचान है। ट्यूमर चयापचय में इसकी भूमिका को उजागर करने के लिए, एल्डिहाइड डिहाइड्रोजेनेज 5 परिवार के सदस्य A1 (ALDH5A1) की पहचान की गई और GBM में miR-210 के प्रत्यक्ष लक्ष्य के रूप में मान्य किया गया। यहां, हम पहली बार GBM चयापचय में miR-210/ALDH5A1 अक्ष की भूमिका की रिपोर्ट करते हैं। हम दिखाते हैं कि ALDH5A1 GBM रोगियों में डाउनरेगुलेट होता है और सेलुलर चयापचय में महत्वपूर्ण भूमिका निभाता है। ग्लूकोज ग्रहण, बाह्यकोशिकीय लैक्टेट, एटीपी, और बाह्यकोशिकीय अम्लीकरण दर (ECAR) जैसे विभिन्न मापदंडों को मापकर, हम प्रदर्शित करते हैं कि miR-210 GBM के ग्लाइकोलाइसिस को बढ़ावा देता है जबकि ALDH5A1 इसे रोकता है। हम यह भी प्रदर्शित करते हैं कि ALDH5A1 ओवरएक्प्रेसन ऑक्सीजन खपत दर (OCR) GBM कोशिकाओं को काफी बढ़ा देता है, जबकि miR-210 माइटोकॉन्ड्रियल श्वसन को रोकता है। अंत में, हमने जीबीएम में ALDH5A1 की एक ट्यूमर दमनकारी भूमिका स्थापित की, जहां इसने सेलुलर प्रसार, 3डी-गोलाकार गठन और प्रतिक्रियाशील ऑक्सीजन प्रजातियों (आरओएस) संचय को रोक दिया। इसके अतिरिक्त, अध्ययन एक संभावित चिकित्सीय लक्ष्य के रूप में miR-210 की खोज करता है और GBM कोशिकाओं में एंटी-miR-210 की इन विट्रो डिलीवरी के लिए डिज़ाइन किया गया एक नया नैनोकैरियर पेश करता है। कोशिकाओं में छोटे आरएनए-आधारित चिकित्सीय पहुंचाने की चुनौतियों को ध्यान में रखते हुए, एक अद्वितीय ट्रांसग्लूटामिनेज़ (टीजीज़)-आधारित नैनोकैरियर विकसित किया गया था, जिसे एक खिलते हुए फूल के आकार में डिज़ाइन किया गया था। ये TGase नैनोफ्लॉवर (TGNFs), PEI के साथ क्रियाशील और 61nm के औसत व्यास के साथ, एंटी-miR-210 के साथ प्रभावी ढंग से जटिल होते हैं, इसके सेलुलर अवशोषण को बढ़ाते हैं और इसके डाउनरेगुलेशन को सुविधाजनक बनाते हैं। टीजीएनएफ ने एंटी-एमआईआर-210 के लिए 90% एनकैप्सुलेशन दक्षता का प्रदर्शन किया, गैर-साइटोटॉक्सिसिटी का प्रदर्शन किया, सीडी1 चूहों के लीवर और किडनी के स्वास्थ्य पर प्रतिकूल प्रभाव नहीं डाला, सीरम न्यूक्लियस से कार्गो की रक्षा की, और अन्य पॉलीअनियन मोएटीज़ द्वारा प्रतिस्थापन को रोका। टीजीएनएफ का उपयोग करके जीबीएम सेल लाइनों यू-87 एमजी और एलएन229 में एंटी-एमआईआर-210 पहुंचाने से एपोप्टोसिस के प्रेरण के साथ-साथ सेलुलर प्रसार और प्रवासन में काफी कमी आई। कुल मिलाकर, यह शोध एमआईआर-210 के एक नए लक्ष्य को मान्य करता है, जीबीएम चयापचय में इसकी भूमिका पर प्रकाश डालता है, और जीबीएम कोशिकाओं तक इसके प्रतिपक्षी पहुंचाने के लिए एक अद्वितीय नैनोकैरियर प्रस्तुत करता है।

TABLE OF CONTENTS

CERTIFICATE	i
ACKNOWLEDGEMENTS	ii
ABSTRACT	iv
TABLE OF CONTENTS	vi
LIST OF FIGURES	xi
LIST OF TABLES	xiii
ABBREVIATIONS	xiv
CHAPTER I: INTRODUCTION	1
CHAPTER II: REVIEW OF LITERATURE	6
Glioblastoma.....	7
Etiology.....	9
Epidemiology.....	9
Classification.....	10
2021 WHO classification.....	10
Molecular subtyping of GBM.....	11
<i>Proneural subtype</i>	11
<i>Neural subtype</i>	11
<i>Classical subtype</i>	12
<i>Mesenchymal subtype</i>	12
Treatment strategies.....	12
Conventional GBM therapy.....	12
<i>Surgery</i>	12
<i>Chemotherapy</i>	13
<i>Radiotherapy</i>	13
<i>Tumor treating fields</i>	14
<i>Bevacizumab mediated immunotherapy</i>	14
Emerging GBM therapy.....	15
<i>Oncolytic virus</i>	15
<i>Tumor vaccines</i>	16
<i>CAR-T cell-based therapy</i>	17
<i>Immune checkpoint inhibitors</i>	17
Challenges to GBM therapy.....	18
Invasive nature of GBM.....	18
Blood-brain barrier (BBB).....	19
Tumor Heterogeneity.....	19
Immune suppression.....	20

Glioma stem cells and therapy resistance.....	20
Altered metabolism in GBM.....	21
Enhanced glycolysis.....	23
Impaired mitochondrial metabolism.....	24
MicroRNAs (miRNAs).....	25
Biogenesis.....	25
Mechanism of action.....	28
MiRNAs in cancer.....	28
MiRNA signature in GBM.....	29
MiRNA-based GBM therapy.....	31
MiRNA replacement therapy.....	31
<i>MiRNA mimics</i>	32
<i>MiRNA overexpression vectors</i>	33
MiRNA inhibition therapy.....	33
<i>Small molecule inhibitors of miRNAs</i>	33
<i>Antisense oligonucleotides (ASOs)</i>	34
<i>MiRNA sponge</i>	35
<i>MiRNA mask</i>	36
<i>CRISPR/CAS9 mediated genome editing</i>	36
Delivery strategies for miRNA-based GBM therapy.....	37
Viral delivery.....	38
Non-viral delivery.....	38
Polymer based delivery agents.....	39
<i>Cationic polymers</i>	39
<i>Non-cationic polymers</i>	40
Lipid-based delivery systems.....	40
<i>Liposomes</i>	40
<i>Solid lipid nanoparticles</i>	41
<i>Stable nucleic acid lipid particle</i>	41
Bio-inspired delivery systems.....	42
<i>Exosomes</i>	42
<i>Cell-penetrating peptides</i>	43
<i>Aptamers</i>	43
Inorganic delivery systems.....	44
MiR-210: expression and regulation.....	46
Physiological role of miR-210.....	47
Clinical relevance of miR-210 in noncancerous diseases.....	48
Clinical relevance of miR-210 in cancer.....	48
MiR-210 as a cancer biomarker.....	48
<i>MiR-210 as a diagnostic biomarker</i>	48

<i>MiR-210 as a prognostic biomarker</i>	51
Therapeutic potential of miR-210 in cancer.....	52
Targets and functional significance of miR-210 in GBM.....	53
CHAPTER III: OBJECTIVES	55
CHAPTER IV: MATERIALS AND METHODS	57
Cell culture.....	58
GBM Patient data analysis.....	58
<i>In silico</i> target prediction of miR-210.....	58
Expression analysis of ALDH5A1 in Indian patient samples.....	58
Anti-miR oligos and recombinant plasmids.....	59
Transient transfection.....	59
Hypoxia treatment.....	60
RNA isolation and RT-qPCR.....	60
Protein isolation.....	60
Western Blotting.....	60
3' UTR dual luciferase assay.....	61
Protein-protein interaction and functional enrichment analysis.....	61
Metabolic assays.....	62
Glucose uptake assay.....	62
<i>Flow cytometric assay</i>	62
<i>Colorimetric assay</i>	62
Lactate production	62
ATP synthesis.....	63
Seahorse XF-analyzer based metabolic assays.....	64
Mitochondrial stress test.....	63
Glycolytic stress test.....	64
ROS measurement.....	64
MTT cell proliferation assay.....	64
Colony formation assay.....	65
Wound healing assay.....	65
3D spheroid formation assay.....	65
Cell cycle analysis.....	66
Caspase 3/7 Glo Assay and FACS analysis for apoptosis assessment.....	66
Synthesis and characterization of TGNFs.....	66
Anti-miR-210 and TGNF complex formation.....	67
Encapsulation efficiency.....	67
Cell viability.....	68
Heparin competition assay.....	68
Serum stability assay.....	69

Cellular uptake.....	69
Flow cytometry.....	69
Fluorescence microscopy.....	70
<i>In vivo</i> toxicity assay to assess liver and kidney health.....	70
Serum biochemical analysis.....	70
Hematoxylin and Eosin staining.....	70
Statistical Analysis.....	71
CHAPTER 5: MIR-210-MEDIATED TARGETING OF ALDH5A1 REPROGRAMS CELLULAR METABOLISM IN GBM.....	72
RESULTS.....	73
MiR-210 is upregulated in GBM.....	73
MiR-210 is associated with poor survival of glioma patients.....	74
ALDH5A1 is a predicted miR-210 target.....	75
MiR-210-ALDH5A1 interaction.....	75
ALDH5A1 levels are inversely correlated with miR-210 in GBM patients.....	76
Ectopic modulation of miR-210 inversely regulates ALDH5A1 levels in GBM cell lines.....	77
MiR-210 knockdown.....	77
MiR-210 overexpression.....	77
Hypoxia regulates miR-210 and ALDH5A1 expression in GBM.....	79
MiR-210 directly targets ALDH5A1 by binding to its 3' UTR.....	80
Tissue distribution and subcellular localization of ALDH5A1.....	81
ALDH5A1 is downregulated in GBM.....	82
ALDH5A1 is associated with favorable survival of GBM patients.....	84
Protein-protein Interaction and functional enrichment of ALDH5A1.....	85
ALDH5A1 is upregulated and miR-210 is downregulated in IDH mutant glioma.....	86
Molecular cloning of ALDH5A1 in mammalian expression vector.....	88
ALDH5A1 inhibits while miR-210 promotes aerobic glycolysis of GBM cells.....	89
Glucose uptake.....	89
Lactate production.....	91
ATP synthesis.....	93
Extracellular acidification rate (ECAR).....	93
Oxygen consumption rate (OCR).....	95
ALDH5A1 inhibits cellular proliferation of GBM.....	98
ALDH5A1 decreases spheroid formation of GBM cells.....	99
Effect of ALDH5A1 on cell cycle progression of GBM cells.....	100
ALDH5A1 decreases reactive oxygen species (ROS) formation in GBM.....	100
DISCUSSION.....	101

CHAPTER 6: TRANSGLUTAMINASE-POLYETHYLENEIMINE NANOFLOWERS MEDIATED CELLULAR DELIVERY OF ANTI-MIR-210 FOR EFFECTIVE GLIOBLASTOMA THERAPY.....	106
RESULTS.....	107
Synthesis of Transglutaminase Nanoflowers as an anti-miR nanocarrier.....	107
Characterization of TGNFs and anti-miR:TGNF complex.....	108
TGNFs successfully form a complex with anti-miRs.....	109
Anti-miR encapsulation efficiency of TGNFs.....	110
TGNFs protect anti-miRs from heparin displacement.....	111
TGNFs protect anti-miRs from serum mediated degradation.....	112
Cellular uptake of anti-miR:TGNF complex.....	112
TGNFs deliver anti-miR-210 to GBM cells and abrogate endogenous miR-210 levels.....	113
Evaluation of the cytotoxic potential of TGNFs.....	114
<i>In vitro</i> cytotoxicity of TGNFs.....	114
<i>In vivo</i> toxicity of TGNFs.....	115
<i>Serum biochemical analysis</i>	115
<i>Histopathological analysis</i>	116
TGNF-mediated anti-miR-210 delivery to GBM cells inhibits cellular proliferation...	117
TGNF-mediated anti-miR-210 delivery to GBM cells inhibits cellular migration.....	118
TGNF-mediated anti-miR-210 delivery to GBM cells promotes G2/M cell cycle arrest.....	119
TGNF-mediated anti-miR-210 delivery promotes apoptosis of GBM cells.....	120
DISCUSSION.....	122
CHAPTER8: CONCLUDING REMARKS AND FUTURE DIRECTIONS.....	126
Concluding remarks.....	127
Future directions.....	129
BIBLIOGRAPHY.....	130
Appendix I.....	162
List of qPCR primer.....	162
MiRNA detection primers.....	162
Appendix II.....	162
Cloning primers.....	162
Appendix III.....	163
SDM primers.....	163
RESUME OF THE AUTHOR.....	164

LIST OF FIGURES

Figure no	Title	Page no
2.1	Components of the human neuroglia	7
2.2	Surgical methods for removal of brain tumors	8
2.3	Categorization of gliomas based on the 2021 WHO classification of CNS tumors	10
2.4	Conventional and emerging modes of GBM therapy	15
2.5	Warburg effect and related therapy	22
2.6	Metabolic reprogramming in GBM	24
2.7	Overview of microRNA biogenesis in humans	27
2.8	MiRNA-based biomarkers and therapeutics in glioma	29
2.9	Chemical modifications of miRNA modulators	35
2.10	Application of miRNA-based therapeutics at various stages of the miRNA biogenesis pathway	37
2.11	Role of miR-210 in various biological processes	47
5.1	MiR-210 is upregulated in GBM	73
5.2	MiR-210 is associated with poor patient survival	74
5.3	ALDH5A1 is a predicted target of miR-210 in GBM	75
5.4	MiR-210 binding site in the 3' UTR of ALDH5A1 transcript	76
5.5	MiR-210 and ALDH5A1 expression correlation	77
5.6	Effect of miR-210 knockdown on ALDH5A1 transcript levels	78
5.7	Effect of miR-210 overexpression on ALDH5A1 levels	79
5.8	ALDH5A1 and miR-210 are regulated by tumor hypoxia in GBM	80
5.9	MiR-210 directly binds to the 3' UTR of ALDH5A1	81
5.10	Tissue distribution and subcellular localization of ALDH5A1	82
5.11	ALDH5A1 is downregulated in GBM at transcript levels	83
5.12	ALDH5A1 protein expression in glioma tissue samples	84
5.13	ALDH5A1 is associated with favorable patient survival	85
5.14	Protein-protein interaction studies of ALDH5A1	86
5.15	Effect of IDH mutation on miR-210 and ALDH5A1 regulation	87
5.16	Molecular cloning and overexpression of ALDH5A1	88
5.17	Effect of ALDH5A1 and miR-210 overexpression on glucose uptake	90
5.18	Flow-cytometric analysis of glucose uptake in GBM cells upon ALDH5A1 and miR-210 overexpression	91
5.19	Effect of ALDH5A1 and miR-210 overexpression on lactate production	92
5.20	Effect of ALDH5A1 and miR-210 overexpression on total ATP synthesis	93
5.21	Extracellular acidification rate of GBM cells upon ALDH5A1 and miR-210 overexpression	95
5.22	Oxygen consumption rate of GBM cells upon ALDH5A1 and miR-210	97

	overexpression	
5.23	ALDH5A1 overexpression inhibits the proliferation of GBM cells	98
5.24	Effect of ALDH5A1 on 3D spheroid formation of GBM cells	99
5.25	ALDH5A1 overexpression promotes G0/G1 cell cycle arrest of GBM cells	100
5.26	ALDH5A1 inhibits ROS formation in GBM cells	101
6.1	Schematic diagram representing the synthesis process of TGNFs	107
6.2	Characterization of TGNFs	108
6.3	Complexation between TGNFs and anti-miRs	110
6.4	Heparin competition assay	111
6.5	Serum stability assay	112
6.6	Cellular uptake and transfection efficiency of the anti-miR/TGNF complex	113
6.7	<i>In vitro</i> cytotoxicity of TGNFs	115
6.8	Serum biochemical analysis of CD1 mice treated with various amounts of TGNFs	116
6.9	Histopathological analysis of mice liver and kidney tissue upon treatment with various concentrations of TGNFs	117
6.10	Effect of anti-miR-210/TGNF delivery on cellular proliferation	118
6.11	Effect of anti-miR-210/TGNF delivery on cellular migration	119
6.12	Effect of anti-miR-210/TGNF delivery on the cell cycle	120
6.13	Effect of anti-miR-210/TGNF delivery on apoptosis of GBM cells	121
7.1	Schematic summarizing the role of miR-210/ALDH5A1 axis in GBM metabolism	127
7.2	Schematic summarizing the delivery of anti-miR-210 to GBM cells using TGNFs	128

LIST OF TABLES

Table no	Title	Page no
1	Prominent tumor suppressor and oncogenic miRNAs associated with GBM	30
2	Delivery strategies implemented in miRNA based therapy of GBM	45
3	MiR-210 expression in various cancers	50

ABBREVIATIONS

[2-N-(7-nitrobenz-2-oxa-1,2-dioxol-4-yl) amino]-2-deoxyglucose	2-NBDG
1,2-dioleoyl-3-dimethylammonium propane	DODAP
1,2-dioleyloxy-N,N-dimethyl-3-aminopropane	DODMA
2'-7'-Dichlorodihydrofluorescein diacetate	DCFDA
3' untranslated region	3' UTR
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide	MTT
3-phosphoinositide-dependent protein kinase 1 (PDPK1)-mediated phosphoglycerate kinase 1	PGK1
Adeno-associated viruses	AAVs
Adenosine diphosphate	ADP
Adenosine triphosphate	ATP
Aldehyde dehydrogenase 5 family member A1	ALDH5A1
Alpha-ketoglutarate	α -KG
Angiopoietin 1	ANG1
Angiopoietin 24	ANG24
Antigen-presenting cells	APCs
Antisense oligonucleotides	ASOs
Apolipoprotein E	ApoE
ATP binding cassette	ABC
Blood brain barrier	BBB
Blood-tumor barrier	BTB
Bovine serum albumin	BSA
Brain-derived neurotrophic factor	BDNF
carbonic anhydrase 9	CA9
Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone	FCCP
Cell-penetrating peptides	CPPs
Central Brain Tumor Registry of the United States	CBTRUS
Central nervous system	CNS
Chimeric Antigen Receptor T-cell	CAR-T

Chinese glioma genome atlas	CGGA
Cholangiocarcinoma	CCA
Clear cell renal cell carcinoma	CCRCC
Clustered regulatory interspaced short palindromic repeats	CRISPR
Colorectal cancer	CRC
Cytochrome c oxidase assembly protein	COX10
D-2-hydroxyglutarate	D-2HG
Damage-associated molecular patterns	DAMPs
DiGeorge syndrome critical region 8	DGCR8
Dimethyl sulfoxide	DMSO
Disease specific survival	DSS
Dulbecco's Modified Eagle Medium	DMEM
Dynamic light scattering	DLS
Electron transport chain	ETC
Encapsulation efficiency	EE
Epidermal growth factor receptor	EGFR
Erythropoietin	EPO
Extracellular acidification rate	ECAR
Field emission scanning electron microscopy	FESEM
Fluorescein amidite	FAM
Food and drug administration	FDA
Fourier transform infrared spectroscopy	FTIR
Gamma-aminobutyric acid	GABA
Gamma-aminobutyric acid type A receptor alpha1	GABRA1
Glioblastoma	GBM
Glioma stem cells	GSCs
Glucose-6-phosphate	G6P
Glyceraldehyde 3-phosphate dehydrogenase	GAPDH
Hepatocellular carcinoma	HCC
Hexokinase 1	HK1

Hypoxia response elements	HREs
Hypoxia-inducible factor A	HIF1A
Interleukin-6	IL-6
Iron-sulfur cluster scaffold homolog	ISCU
Isocitrate dehydrogenase	IDH
Locked nucleic acid	LNA
Magnetic resonance	MR
miRNA	MicroRNA
Monoclonal antibody	mAb
Nanographene oxide	NGO
Neurofilament light polypeptide	NEFL
Nicotinamide Adenine Dinucleotide Phosphate Hydrogen	NADPH
Noncoding RNA	ncRNA
Nonhomologous end joining	NHEJ
Non-small cell lung cancer	NSCLC
Nuclear factor kappa B	NF-kB
O6-methylguanine DNA methyltransferase	MGMT
Oncogenic miRNAs	OncomiRs
Oncogenic virus	OV
Oral squamous cell carcinoma	OSCC
Overall survival	OS
Oxidative phosphorylation	OXYPHOS
Oxygen consumption rate	OCR
Pathogen-associated molecular patterns	PAMPs
Phenylmethylsulfonyl fluoride	PMSF
Phosphatase and tensin homolog	PTEN
Phosphate-buffered saline	PBS
Phosphoenol pyruvate	PEP
Platelet Derived Growth Factor Receptor Alpha	PDGFRA
Poly (ADP-ribose) polymerase	PARP

Poly (lactic-co-glycolic acid)	PLGA
Polyacrylamide gel electrophoresis	PAGE
Poly-dimethylaminoethyl methacrylate	PDMAEMA
Polyethylene glycol	PEG
Polyethylenimine	PEI
Polyglycerol	PG
Poly- β -amino esters	PBAE
Post transcriptional gene silencing	PTGS
Programmed cell death ligand 1	PD-L1
Progression free survival	PFS
Proliferating cell nuclear antigen	PCNA
Prolyl 4-hydroxylase, beta polypeptide	P4HB
Pyruvate dehydrogenase kinase 1	PDK1
Pyruvate kinase M	PKM
Quantitative real time polymerase chain reaction	qRT-PCR
Rabies virus glycoprotein	RVG
Reactive oxygen species	ROS
Receptor tyrosine kinases	RTKs
Regulator of differentiation 1	ROD1
Retinoblastoma-associated protein	RB
Ribose-5-phosphate	R5P
RNA-induced silencing complex	RISC
Severe adverse events	SAEs
Sex determining region Y-box 2	SOX2
Site directed mutagenesis	SDM
Small molecule inhibitors of miRNAs	SMIRs
Sodium dodecyl sulfate	SDS
Solid lipid nanoparticles	SLNs
Solute carrier family 12 members 5	SLC12A5
Spherical nucleic acids	SNAs

Stable nucleic acid-lipid particles	SNALPs
Subunit D of succinate dehydrogenase complex	SDHD
Succinic semialdehyde dehydrogenase	SSADH
Synaptotagmin 1	SYT1
TAR RNA-binding protein	TRBP
Telomerase Reverse Transcriptase	TERT
Temozolomide	TMZ
The cancer genome atlas	TCGA
Toll like receptors	TLRs
Transglutaminase	TGase
Transglutaminase nanoflowers	TGNFs
Transmission electron microscopy	TEM
Tris-buffered saline with 0.1% Tween 20	TBST
Tumor Treating Fields	TTFs
Vascular endothelial growth factor A	VEGFA
Wharton's jelly mesenchymal stem cells	WJMSCs
World health organization	WHO